Using a Multiplex Suspension Bead Assay to Establish a Serocorrelate of Protection for Group B Streptococcus Disease

Speaker
  • Senior Technician at St George's, University of London

Abstract

Purpose:
Group B Streptococcus (GBS) is a Gram positive coccus which is part of the normal microbiota of the GI and GU tracts. However GBS is also a major cause of septicaemia and meningitis in newborns. Colonisation with GBS during pregnancy is a major risk factor for neonatal infection. Intrapartum antibiotic prophylaxis has greatly reduced incidence of early onset disease. However concerns over emerging antibiotic resistance and its impact on neonatal intestinal microbiota and a lack of protection afforded by intrapartum antibiotics outside of the first few days of life have led to GBS becoming a candidate for maternal vaccine development. Maternal IgG antibodies targeting capsular polysaccharides have been observed to provide protection against disease (Fabbrini et al 2016). Establishing a serocorrelate of protection could assist in the pathway to licensure of a GBS vaccine.

Methods:
A Bill and Melinda Gates Foundation funded consortium led by Kirsty Le Doare to establish a standardised multiplex immunoassay (MIA), based up luminex’s Xmap technology, and an opsonophagocytic killing assay (OPkA). This will be followed by a inter laboratory study between multiple partners to establish assay parameters and reproducibility.

Results:
Standardised reagents (CPS-PLL conjugates, standards) are being developed and characterised and preparations are being made for the inter laboratory study.

Conclusion:
Identifying a level of IgG which provides protection from GBS disease has been hampered by a lack of assay standardisation. A consortium has been established to develop standardised reagents and assays, including the multiplex immunoassay. Future studies to assess the relationship between antibody level, colonisation and disease are being planned.


Show Resources
You May Also Like
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
OCT 12, 2022 8:00 AM PDT
OCT 12, 2022 8:00 AM PDT
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
SEP 28, 2022 9:00 AM PDT
SEP 28, 2022 9:00 AM PDT
Date: September 28, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) While COVID-19 continues to be the most pressing diagnostic focus for clinical laboratories, HIV remains a serious g...
NOV 09, 2022 8:00 AM PST
NOV 09, 2022 8:00 AM PST
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...

Using a Multiplex Suspension Bead Assay to Establish a Serocorrelate of Protection for Group B Streptococcus Disease



Show Resources
Loading Comments...
Show Resources
Attendees